- Home
- EHGO vs IKNA Comparison
EHGO vs IKNA Comparison
Compare EHGO & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHGO
- IKNA
- Stock Information
- Founded
- EHGO 2015
- IKNA 2016
- Country
- EHGO China
- IKNA United States
- Employees
- EHGO N/A
- IKNA N/A
- Industry
- EHGO
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- EHGO
- IKNA Health Care
- Exchange
- EHGO NYSE
- IKNA Nasdaq
- Market Cap
- EHGO 23.0M
- IKNA 63.7M
- IPO Year
- EHGO 2024
- IKNA 2021
- Fundamental
- Price
- EHGO $0.81
- IKNA $1.37
- Analyst Decision
- EHGO
- IKNA Strong Buy
- Analyst Count
- EHGO 0
- IKNA 1
- Target Price
- EHGO N/A
- IKNA $4.00
- AVG Volume (30 Days)
- EHGO 3.3M
- IKNA 63.1K
- Earning Date
- EHGO 07-22-2025
- IKNA 08-07-2025
- Dividend Yield
- EHGO N/A
- IKNA N/A
- EPS Growth
- EHGO N/A
- IKNA N/A
- EPS
- EHGO N/A
- IKNA N/A
- Revenue
- EHGO $15,393,105.00
- IKNA N/A
- Revenue This Year
- EHGO N/A
- IKNA N/A
- Revenue Next Year
- EHGO N/A
- IKNA N/A
- P/E Ratio
- EHGO N/A
- IKNA N/A
- Revenue Growth
- EHGO N/A
- IKNA N/A
- 52 Week Low
- EHGO $0.71
- IKNA $0.97
- 52 Week High
- EHGO $5.50
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- EHGO N/A
- IKNA 55.10
- Support Level
- EHGO N/A
- IKNA $1.31
- Resistance Level
- EHGO N/A
- IKNA $1.42
- Average True Range (ATR)
- EHGO 0.00
- IKNA 0.05
- MACD
- EHGO 0.00
- IKNA -0.00
- Stochastic Oscillator
- EHGO 0.00
- IKNA 51.24
About EHGO ESHALLGO INC
Eshallgo Inc. focuses on two distinct market sectors: office supply sale and leasing, and after-sale maintenance and repair. It is an authorized distributor of brands of office equipment, including HP, Epson, Xerox, Sharp, Toshiba, Konica, Kyocera, and other brands.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.